Discounted Cash Flow (DCF) Analysis Levered
Dermapharm Holding SE (DMP.DE)
38.78 €
+0.32 (+0.83%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 572.42 | 700.88 | 793.83 | 942.91 | 1,024.78 | 1,186.60 | 1,373.98 | 1,590.95 | 1,842.18 | 2,133.08 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | 159.13 | 100.61 | 131.10 | 250.37 | 288.53 | 269.07 | 311.56 | 360.75 | 417.72 | 483.69 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -25.97 | -46.44 | -40.80 | -61.20 | -39.01 | -63.13 | -73.10 | -84.64 | -98.01 | -113.48 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | 133.15 | 54.17 | 90.30 | 189.16 | 249.52 | 205.94 | 238.46 | 276.11 | 319.72 | 370.20 |
Weighted Average Cost Of Capital
Share price | $ 38.78 |
---|---|
Beta | 1.136 |
Diluted Shares Outstanding | 53.84 |
Cost of Debt | |
Tax Rate | 37.94 |
After-tax Cost of Debt | 1.48% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 9.987 |
Total Debt | 516.45 |
Total Equity | 2,087.92 |
Total Capital | 2,604.36 |
Debt Weighting | 19.83 |
Equity Weighting | 80.17 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 572.42 | 700.88 | 793.83 | 942.91 | 1,024.78 | 1,186.60 | 1,373.98 | 1,590.95 | 1,842.18 | 2,133.08 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | 159.13 | 100.61 | 131.10 | 250.37 | 288.53 | 269.07 | 311.56 | 360.75 | 417.72 | 483.69 |
Capital Expenditure | -25.97 | -46.44 | -40.80 | -61.20 | -39.01 | -63.13 | -73.10 | -84.64 | -98.01 | -113.48 |
Free Cash Flow | 133.15 | 54.17 | 90.30 | 189.16 | 249.52 | 205.94 | 238.46 | 276.11 | 319.72 | 370.20 |
WACC | ||||||||||
PV LFCF | 190.16 | 203.31 | 217.37 | 232.41 | 248.48 | |||||
SUM PV LFCF | 1,091.73 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 8.30 |
Free cash flow (t + 1) | 377.61 |
Terminal Value | 5,993.76 |
Present Value of Terminal Value | 4,023.06 |
Intrinsic Value
Enterprise Value | 5,114.79 |
---|---|
Net Debt | 366.53 |
Equity Value | 4,748.26 |
Shares Outstanding | 53.84 |
Equity Value Per Share | 88.19 |